Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy

American Journal of Pathology

Volumn 180, Issue 1, 2012, Pages 375-389

  Kinoshita, Yayoi ^a   Kalir, Tamara ^a   Rahaman, Jamal ^a   Dottino, Peter ^a   Kohtz, D Stave ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NUCLEOPORIN; NUCLEOPORIN 62 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DORMANCY; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEAR PORE COMPLEX; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PORE; NUCLEAR PORE COMPLEX PROTEINS; OVARIAN NEOPLASMS; PHENOTYPE; RNA, SMALL INTERFERING;

EID: 83455164843     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.09.024     Document Type: Article

References (91)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. P. Borst, S. Rottenberg, J. Jonkers How do real tumors become resistant to cisplatin? Cell Cycle 7 2008 1353 1359 (Pubitemid 351872573)
3. M. Knipp Metallothioneins and platinum(II) anti-tumor compounds Curr Med Chem 16 2009 522 537
4. E.E. Noel, M. Yeste-Velasco, X. Mao, J. Perry, S.C. Kudahetti, N.F. Li, S. Sharp, T. Chaplin, L. Xue, A. McIntyre, L. Shan, T. Powles, R.T. Oliver, B.D. Young, J. Shipley, D.M. Berney, S.P. Joel, Y.J. Lu The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers Am J Pathol 2010 2010 15
5. A.M. Codegoni, M. Broggini, M.R. Pitelli, M. Pantarotto, V. Torri, C. Mangioni, M. D'Incalci Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer Gynecol Oncol 65 1997 130 137 (Pubitemid 27171563)
6. M. Selvakumaran, D.A. Pisarcik, R. Bao, A.T. Yeung, T.C. Hamilton Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res 63 2003 1311 1316 (Pubitemid 36348710)
7. D.M. Townsend, V.L. Findlay, K.D. Tew Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets Methods Enzymol 401 2005 287 307 (Pubitemid 43052400)
8. Y. Wang, X.L. Niu, Y. Qu, J. Wu, Y.Q. Zhu, W.J. Sun, L.Z. Li Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells Cancer Lett 2010 2010 14
9. C.A. Sherman-Baust, A.T. Weeraratna, L.B. Rangel, E.S. Pizer, K.R. Cho, D.R. Schwartz, T. Shock, P.J. Morin Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells Cancer Cell 3 2003 377 386 (Pubitemid 38340306)
10. P. Perego, M. Giarola, S.C. Righetti, R. Supino, C. Caserini, D. Delia, M.A. Pierotti, T. Miyashita, J.C. Reed, F. Zunino Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res 56 1996 556 562 (Pubitemid 26043653)
11. X. Wang, Y. Liu, L.S. Chow, S.C. Wong, S.W. Tsao, D.L. Kwong, J. Wang, J.S. Sham, J.M. Nicholls Cisplatin-induced p53-independent growth arrest and cell death in cancer cells Int J Oncol 15 1999 1097 1102
12. M. Schuijer, E.M. Berns TP53 and ovarian cancer Hum Mutat 21 2003 285 291 (Pubitemid 36292970)
13. A. Mansouri, Q. Zhang, L.D. Ridgway, L. Tian, F.X. Claret Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation Oncol Res 13 2003 399 404 (Pubitemid 38166371)
14. J.J. Ma, B.L. Chen, X.Y. Xin XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma Eur J Obstet Gynecol Reprod Biol 146 2009 222 226
15. E. Asselin, G.B. Mills, B.K. Tsang XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells Cancer Res 61 2001 1862 1868 (Pubitemid 32692000)
16. X. Yang, M. Fraser, M.R. Abedini, T. Bai, B.K. Tsang Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt Br J Cancer 98 2008 803 808 (Pubitemid 351272611)
17. M.R. Abedini, E.J. Muller, R. Bergeron, D.A. Gray, B.K. Tsang Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein Oncogene 29 2009 11 25
18. R. Salani, R.J. Kurman, R. Giuntoli 2nd, G. Gardner, R. Bristow, T.L. Wang, I.M. Shih Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance Int J Gynecol Cancer 18 2008 487 491 (Pubitemid 351668307)
19. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, R. Sharma, C. Stewart, S. Fereday, C. Caldas, A. Defazio, D. Bowtell, J.D. Brenton Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
20. S. Cara, I.F. Tannock Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance Ann Oncol 12 2001 23 27 (Pubitemid 32162444)
21. V. Seltzer, S. Vogl, B. Kaplan Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent Gynecol Oncol 21 1985 167 176 (Pubitemid 15052590)
22. S. Rottenberg, A.O. Nygren, M. Pajic, F.W. van Leeuwen, I. van der Heijden, K. van de Wetering, X. Liu, K.E. de Visser, K.G. Gilhuijs, O. van Tellingen, J.P. Schouten, J. Jonkers, P. Borst Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proc Natl Acad Sci U S A 104 2007 12117 12122 (Pubitemid 47185639)
23. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M.A. Fischbach, K.K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
24. M. Beck, F. Forster, M. Ecke, J.M. Plitzko, F. Melchior, G. Gerisch, W. Baumeister, O. Medalia Nuclear pore complex structure and dynamics revealed by cryoelectron tomography Science 306 2004 1387 1390 (Pubitemid 39532518)
25. F. Alber, S. Dokudovskaya, L.M. Veenhoff, W. Zhang, J. Kipper, D. Devos, A. Suprapto, O. Karni-Schmidt, R. Williams, B.T. Chait, A. Sali, M.P. Rout The molecular architecture of the nuclear pore complex Nature 450 2007 695 701 (Pubitemid 350207701)
26. R.Y. Lim, B. Fahrenkrog The nuclear pore complex up close Curr Opin Cell Biol 18 2006 342 347
27. J.M. Boer, J.M. van Deursen, H.J. Croes, J.A. Fransen, G.C. Grosveld The nucleoporin CAN/Nup214 binds to both the cytoplasmic and the nucleoplasmic sides of the nuclear pore complex in overexpressing cells Exp Cell Res 232 1997 182 185 (Pubitemid 27172233)
28. R. Bastos, L. Ribas de Pouplana, M. Enarson, K. Bodoor, B. Burke Nup84, a novel nucleoporin that is associated with CAN/Nup214 on the cytoplasmic face of the nuclear pore complex J Cell Biol 137 1997 989 1000 (Pubitemid 27251036)
29. B. Fahrenkrog, B. Maco, A.M. Fager, J. Koser, U. Sauder, K.S. Ullman, U. Aebi Domain-specific antibodies reveal multiple-site topology of Nup153 within the nuclear pore complex J Struct Biol 140 2002 254 267 (Pubitemid 36139866)
30. S. Hutten, S. Walde, C. Spillner, J. Hauber, R.H. Kehlenbach The nuclear pore component Nup358 promotes transportin-dependent nuclear import J Cell Sci 122 2009 1100 1110
31. T. Hu, T. Guan, L. Gerace Molecular and functional characterization of the p62 complex, an assembly of nuclear pore complex glycoproteins J Cell Biol 134 1996 589 601 (Pubitemid 26269133)
32. T. Guan, S. Muller, G. Klier, N. Pante, J.M. Blevitt, M. Haner, B. Paschal, U. Aebi, L. Gerace Structural analysis of the p62 complex, an assembly of O-linked glycoproteins that localizes near the central gated channel of the nuclear pore complex Mol Biol Cell 6 1995 1591 1603
33. E.R. Griffis, S. Xu, M.A. Powers Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes Mol Biol Cell 14 2003 600 610 (Pubitemid 36237019)
34. L.J. Terry, S.R. Wente Flexible gates: dynamic topologies and functions for FG nucleoporins in nucleocytoplasmic transport Eukaryot Cell 8 2009 1814 1827
35. M. Capelson, Y. Liang, R. Schulte, W. Mair, U. Wagner, M.W. Hetzer Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes Cell 140 2010 372 383
36. B. Kalverda, H. Pickersgill, V.V. Shloma, M. Fornerod Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm Cell 140 2010 360 371
37. B. Kalverda, M. Fornerod The nuclear life of nucleoporins Dev Cell 13 2007 164 165 (Pubitemid 47163613)
38. D.M. Provencher, H. Lounis, L. Champoux, M. Tetrault, E.N. Manderson, J.C. Wang, P. Eydoux, R. Savoie, P.N. Tonin, A.M. Mes-Masson Characterization of four novel epithelial ovarian cancer cell lines In Vitro Cell Dev Biol Anim 36 2000 357 361 (Pubitemid 30626747)
39. G. Singer, R. Stohr, L. Cope, R. Dehari, A. Hartmann, D.F. Cao, T.L. Wang, R.J. Kurman, M. Shih Ie Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2005 218 224 (Pubitemid 40170640)
40. R. Vang, M. Shih Ie, R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 2009 267 282
41. M.H. Roh, Y. Yassin, A. Miron, K.K. Mehra, M. Mehrad, N.M. Monte, G.L. Mutter, M.R. Nucci, G. Ning, F.D. McKeon, M.S. Hirsch, X. Wa, C.P. Crum High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression Mod Pathol 23 2010 1316 1324
42. H. Lincet, L. Poulain, J.S. Remy, E. Deslandes, F. Duigou, P. Gauduchon, C. Staedel The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells Cancer Lett 161 2000 17 26
43. X. Deng, M. Kim, D. Vandier, Y.J. Jung, T. Rikiyama, M.K. Sgagias, M. Goldsmith, K.H. Cowan Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin Biochem Biophys Res Commun 296 2002 792 798
44. K.S. Smalley, T.G. Eisen Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells Int J Cancer 105 2003 165 175 (Pubitemid 36505316)
45. H.M. Coley, C.F. Shotton, M.I. Kokkinos, H. Thomas The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines Gynecol Oncol 105 2007 462 469 (Pubitemid 46591975)
46. P. Vlachos, U. Nyman, N. Hajji, B. Joseph The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway Cell Death Differ 14 2007 1497 1507 (Pubitemid 47086736)
47. Y. Bu, C. Lu, C. Bian, J. Wang, J. Li, B. Zhang, Z. Li, G. Brewer, R.C. Zhao Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin Oncol Rep 21 2009 13 17
48. R.K. Singh, T.S. Lange, K.K. Kim, L. Brard A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells Invest New Drugs 29 2009 29
49. J.A. Aguirre-Ghiso Models, mechanisms and clinical evidence for cancer dormancy Nat Rev Cancer 7 2007 834 846 (Pubitemid 350006258)
50. K. Maeshima, K. Yahata, Y. Sasaki, R. Nakatomi, T. Tachibana, T. Hashikawa, F. Imamoto, N. Imamoto Cell-cycle-dependent dynamics of nuclear pores: pore-free islands and lamins J Cell Sci 119 2006 4442 4451 (Pubitemid 44830643)
51. Y. Kinoshita, E.M. Johnson Site-specific loading of an MCM protein complex in a DNA replication initiation zone upstream of the c-MYC gene in the HeLa cell cycle J Biol Chem 279 2004 35879 35889 (Pubitemid 39100595)
52. E. Meier, B.R. Miller, D.J. Forbes Nuclear pore complex assembly studied with a biochemical assay for annulate lamellae formation J Cell Biol 129 1995 1459 1472
53. A. Ewald, U. Kossner, U. Scheer, M.C. Dabauvalle A biochemical and immunological comparison of nuclear and cytoplasmic pore complexes J Cell Sci 109 Pt 7 1996 1813 1824 (Pubitemid 26248627)
54. T.C. Walther, A. Alves, H. Pickersgill, I. Loiodice, M. Hetzer, V. Galy, B.B. Hulsmann, T. Kocher, M. Wilm, T. Allen, I.W. Mattaj, V. Doye The conserved Nup107-160 complex is critical for nuclear pore complex assembly Cell 113 2003 195 206 (Pubitemid 36514971)
55. L.I. Davis, G. Blobel Nuclear pore complex contains a family of glycoproteins that includes p62: glycosylation through a previously unidentified cellular pathway Proc Natl Acad Sci U S A 84 1987 7552 7556
56. J.R. Paulson, S.S. Taylor Phosphorylation of histones 1 and 3 and nonhistone high mobility group 14 by an endogenous kinase in HeLa metaphase chromosomes J Biol Chem 257 1982 6064 6072
57. J. Bloom, F.R. Cross Multiple levels of cyclin specificity in cell-cycle control Nat Rev Mol Cell Biol 8 2007 149 160 (Pubitemid 46432532)
58. G.A. Belov, P.V. Lidsky, O.V. Mikitas, D. Egger, K.A. Lukyanov, K. Bienz, V.I. Agol Bidirectional increase in permeability of nuclear envelope upon poliovirus infection and accompanying alterations of nuclear pores J Virol 78 2004 10166 10177 (Pubitemid 39187134)
59. E. Hulleman, J. Boonstra Regulation of G1 phase progression by growth factors and the extracellular matrix Cell Mol Life Sci 58 2001 80 93 (Pubitemid 32143965)
60. P. Malik, N. Zuleger, E.C. Schirmer Nuclear envelope influences on genome organization Biochem Soc Trans 38 2010 268 272
61. P. Meister, B.D. Towbin, B.L. Pike, A. Ponti, S.M. Gasser The spatial dynamics of tissue-specific promoters during C. elegans development Genes Dev 24 2010 766 782
62. N. Almog Molecular mechanisms underlying tumor dormancy Cancer Lett 294 2010 139 146
63. H.R. Harach, K.O. Franssila, V.M. Wasenius Occult papillary carcinoma of the thyroid: a "normal" finding in Finland A systematic autopsy study Cancer 56 1985 531 538 (Pubitemid 15035581)
64. M. Nielsen, J.L. Thomsen, S. Primdahl, U. Dyreborg, J.A. Andersen Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies Br J Cancer 56 1987 814 819 (Pubitemid 18048359)
65. W.C. Black, H.G. Welch Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy N Engl J Med 328 1993 1237 1243 (Pubitemid 23115703)
66. T. Udagawa Tumor dormancy of primary and secondary cancers Apmis 116 2008 615 628
67. J.T. Zilfou, S.W. Lowe Tumor suppressive functions of p53 Cold Spring Harb Perspect Biol 1 2009 a001883
68. V. Zuckerman, K. Wolyniec, R.V. Sionov, S. Haupt, Y. Haupt Tumour suppression by p53: the importance of apoptosis and cellular senescence J Pathol 219 2009 3 15
69. F.K. McDuff, S.D. Turner Jailbreak: oncogene-induced senescence and its evasion Cell Signal 23 2011 6 13
70. W. Xue, L. Zender, C. Miething, R.A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, S.W. Lowe Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 445 2007 656 660 (Pubitemid 46232886)
71. L. Holmgren, M.S. O'Reilly, J. Folkman Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 1995 149 153
72. L. Holmgren, G. Jackson, J. Arbiser p53 Induces angiogenesis-restricted dormancy in a mouse fibrosarcoma Oncogene 17 1998 819 824 (Pubitemid 28430204)
73. Y. Nagayama, K. Shigematsu, H. Namba, K. Zeki, S. Yamashita, M. Niwa Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo Anticancer Res 20 2000 2723 2728 (Pubitemid 30614491)
74. S. Mehta, E. Huillard, S. Kesari, C.L. Maire, D. Golebiowski, E.P. Harrington, J.A. Alberta, M.F. Kane, M. Theisen, K.L. Ligon, D.H. Rowitch, C.D. Stiles The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma Cancer Cell 19 2011 359 371
75. M.L. Agarwal, A. Agarwal, W.R. Taylor, G.R. Stark p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts Proc Natl Acad Sci U S A 92 1995 8493 8497
76. A. Fajac, J. Da Silva, J.C. Ahomadegbe, J.G. Rateau, J.F. Bernaudin, G. Riou, J. Benard Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line Int J Cancer 68 1996 67 74 (Pubitemid 26354581)
77. Q. Wei, G. Dong, T. Yang, J. Megyesi, P.M. Price, Z. Dong Activation and involvement of p53 in cisplatin-induced nephrotoxicity Am J Physiol Renal Physiol 293 2007 F1282 F1291
78. B.A. Molitoris, P.C. Dagher, R.M. Sandoval, S.B. Campos, H. Ashush, E. Fridman, A. Brafman, A. Faerman, S.J. Atkinson, J.D. Thompson, H. Kalinski, R. Skaliter, S. Erlich, E. Feinstein siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury J Am Soc Nephrol 20 2009 1754 1764
79. G.H. Eltabbakh, J.L. Belinson, A.W. Kennedy, C.V. Biscotti, G. Casey, R.R. Tubbs, L.E. Blumenson p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer Cancer 80 1997 892 898 (Pubitemid 27360471)
80. P. de Graeff, A.P. Crijns, S. de Jong, M. Boezen, W.J. Post, E.G. de Vries, A.G. van der Zee, G.H. de Bock Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159
81. T. Strobel, L. Swanson, S. Korsmeyer, S.A. Cannistra BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway Proc Natl Acad Sci U S A 93 1996 14094 14099 (Pubitemid 26424251)
82. L.J. Stubbert, J.M. Smith, B.C. McKay Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin BMC Cancer 10 2010 207
83. A. Basu, S. Krishnamurthy Cellular responses to cisplatin-induced DNA damage J Nucleic Acids 2010 2010 201367
84. K. Lawrenson, S.A. Gayther Ovarian cancer: a clinical challenge that needs some basic answers PLoS Med 6 2009 e25
85. I. Espinosa, L. Catasus, B. Canet, E. D'Angelo, J. Munoz, J. Prat Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis Mod Pathol 2011 2011 11
86. T. Taniguchi, M. Tischkowitz, N. Ameziane, S.V. Hodgson, C.G. Mathew, H. Joenje, S.C. Mok, A.D. D'Andrea Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 2003 568 574 (Pubitemid 36597103)
87. I. Solovei, M. Kreysing, C. Lanctot, S. Kosem, L. Peichl, T. Cremer, J. Guck, B. Joffe Nuclear architecture of rod photoreceptor cells adapts to vision in mammalian evolution Cell 137 2009 356 368
88. L.S. Elcock, J.M. Bridger Exploring the relationship between interphase gene positioning, transcriptional regulation and the nuclear matrix Biochem Soc Trans 38 Pt 1 2010 263 267
89. L.A. Hawryluk-Gara, E.K. Shibuya, R.W. Wozniak Vertebrate Nup53 interacts with the nuclear lamina and is required for the assembly of a Nup93-containing complex Mol Biol Cell 16 2005 2382 2394 (Pubitemid 40632220)
90. H. Pickersgill, B. Kalverda, E. de Wit, W. Talhout, M. Fornerod, B. van Steensel Characterization of the Drosophila melanogaster genome at the nuclear lamina Nat Genet 38 2006 1005 1014 (Pubitemid 44325925)
91. L. Guelen, L. Pagie, E. Brasset, W. Meuleman, M.B. Faza, W. Talhout, B.H. Eussen, A. de Klein, L. Wessels, W. de Laat, B. van Steensel Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions Nature 453 2008 948 951 (Pubitemid 351832561)